九典制药
(300705)
| 流通市值：75.55亿 | | | 总市值：125.01亿 |
| 流通股本：2.09亿 | | | 总股本：3.45亿 |
| 报告期 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 590,896,382.47 | 2,692,511,461.24 | 1,892,932,754.63 | 1,217,715,098.36 |
| 营业收入 | 590,896,382.47 | 2,692,511,461.24 | 1,892,932,754.63 | 1,217,715,098.36 |
| 二、营业总成本 | 472,495,995.84 | 2,314,990,942.39 | 1,548,770,713.93 | 1,014,593,754.99 |
| 营业成本 | 161,665,602.27 | 615,217,177.11 | 416,608,659.13 | 271,082,690.3 |
| 税金及附加 | 6,853,696.4 | 34,212,152.61 | 24,665,708.81 | 15,284,250.86 |
| 销售费用 | 239,316,247.27 | 1,307,431,808.44 | 881,744,432.42 | 593,326,468.78 |
| 管理费用 | 19,699,811.98 | 97,987,986.03 | 66,433,692.4 | 43,876,255.42 |
| 研发费用 | 40,928,107.97 | 254,121,849.65 | 157,352,877.64 | 91,007,506.81 |
| 财务费用 | 4,032,529.95 | 6,019,968.55 | 1,965,343.53 | 16,582.82 |
| 其中:利息费用 | 5,221,015.81 | 11,061,725.58 | 5,143,363.87 | 2,143,398.38 |
| 其中:利息收入 | 1,414,246.85 | 5,535,934.21 | 3,559,993.02 | 2,302,857.5 |
| 加:公允价值变动收益 | 0 | 0 | 0 | - |
| 加:投资收益 | 580,456.19 | 2,132,585.94 | 1,504,923.76 | 1,098,307.06 |
| 净敞口套期收益 | 0 | 0 | 0 | - |
| 资产处置收益 | 0 | 30,283.93 | 30,283.93 | 30,283.93 |
| 资产减值损失(新) | -2,542,389.59 | -6,570,476.86 | -2,165,581.72 | -1,725,300.02 |
| 信用减值损失(新) | 5,980,539.21 | -7,808,360.95 | -2,935,794.94 | -2,106,237.38 |
| 其他收益 | 24,872,049.39 | 29,065,685.43 | 14,790,595.91 | 12,341,380.65 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 147,291,041.83 | 394,370,236.34 | 355,386,467.64 | 212,759,777.61 |
| 加:营业外收入 | 285,274.53 | 10,405,332.94 | 10,904,853.9 | 9,791,881.23 |
| 减:营业外支出 | 1,946,013.49 | 2,614,585.61 | 1,821,791.02 | 193,300.49 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 145,630,302.87 | 402,160,983.67 | 364,469,530.52 | 222,358,358.35 |
| 减:所得税费用 | 19,960,829.75 | 33,900,192.99 | 54,479,094.46 | 24,730,164.36 |
| 六、净利润 | 125,669,473.12 | 368,260,790.68 | 309,990,436.06 | 197,628,193.99 |
| 持续经营净利润 | 125,669,473.12 | 368,260,790.68 | 309,990,436.06 | 197,628,193.99 |
| 终止经营净利润 | 0 | 0 | 0 | - |
| 归属于母公司股东的净利润 | 125,669,473.12 | 368,260,790.68 | 309,990,436.06 | 197,628,193.99 |
| 少数股东损益 | 0 | - | 0 | - |
| (一)基本每股收益 | 0.36 | 1.07 | 0.9 | 0.58 |
| (二)稀释每股收益 | 0.36 | 1.07 | 0.9 | 0.58 |
| 八、其他综合收益 | 0 | 0 | 0 | - |
| 归属于母公司股东的其他综合收益 | 0 | 0 | 0 | - |
| 九、综合收益总额 | 125,669,473.12 | 368,260,790.68 | 309,990,436.06 | 197,628,193.99 |
| 归属于母公司股东的综合收益总额 | 125,669,473.12 | 368,260,790.68 | 309,990,436.06 | 197,628,193.99 |
| 归属于少数股东的综合收益总额 | 0 | 0 | 0 | - |
| 公告日期 | 2024-04-25 | 2024-04-25 | 2023-10-24 | 2023-08-16 |
| 审计意见(境内) | | 标准无保留意见 | | |